STOCK TITAN

Aequus Pharmaceu - AQSZF STOCK NEWS

Welcome to our dedicated page for Aequus Pharmaceu news (Ticker: AQSZF), a resource for investors and traders seeking the latest updates and insights on Aequus Pharmaceu stock.

Aequus Pharmaceuticals Inc. (OTCQB: AQSZF) is a Canadian specialty pharmaceutical company developing innovative treatments in ophthalmology, transplant care, and rare diseases. This dedicated news hub provides investors and healthcare professionals with essential updates on product developments, regulatory milestones, and strategic partnerships.

Access timely announcements regarding the company's Evolve® product line, including progress on MDSAP certification for Canadian market re-entry. Stay informed about therapeutic advancements across key treatment areas and expansion initiatives through collaborative ventures.

Our curated news collection features official press releases on regulatory submissions, partnership agreements, and corporate developments. Regular updates ensure stakeholders maintain current understanding of Aequus' progress in enhancing patient care through differentiated pharmaceutical solutions.

Bookmark this page for direct access to verified company communications. Check back frequently for the latest information on product availability updates and market expansion strategies within Canada's healthcare sector.

Rhea-AI Summary
Aequus Pharmaceuticals reports financial results for Q2 2023. Revenue decreased by 71% compared to last year. Net losses decreased by 9.22% in Q2 2023. Sales of Evolve branded eyedrops paused in Canada. General administration costs decreased by 23% in Q2 2023. Sales and marketing costs decreased by 44% in Q2 2023. R&D expenses increased in Q2 2023. G&A expenses decreased by 36% in YTD 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.91%
Tags
-
Rhea-AI Summary
Aequus Pharmaceuticals launches preservative-free Bimatoprost for glaucoma patients in Canada
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Rhea-AI Summary
Aequus Pharmaceuticals launches user-friendly education website for patients and professionals, featuring preservative-free multi-dose Bimatoprost. Positive response from Canadian physicians at COS conference. Website aims to empower users with comprehensive resources and expert guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Aequus Pharmaceuticals pauses sales of Evolve Intensive eyedrop and gel products in Canada due to MDSAP certification process. Sales will resume once certification is issued.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Aequus Pharmaceuticals reports financial results for Fiscal 2022, with an operating loss of $2.7 million. The company is focusing on launching its prescription product, ZIMED®, in the next 3 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.75%
Tags
-
News
Rhea-AI Summary

Aequus Pharmaceuticals Inc. (OTCQB: AQSZF) has announced the granting of incentive stock options to directors, officers, employees, and consultants, totaling 2,775,000 common shares. These options will be exercisable at a price of $0.03 per share over a term of eight years and will vest over three years. This move aligns with the Company's stock option plan and the TSX Venture Exchange policies. Aequus is focused on developing and commercializing specialized pharmaceutical products, particularly in ophthalmology and seeks to expand its Canadian platform through internal development or acquisitions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Aequus Pharmaceuticals (TSX-V: AQS, OTCQB: AQSZF) has secured a $500,000 loan from CEO Doug Janzen to support the launch of Zimed® PF, a new preservative-free treatment for elevated intraocular pressure in glaucoma patients. The loan carries a 2.5% interest rate and is repayable on demand. Zimed® PF received Health Canada approval last December and is the only multi-dose preservative-free prostaglandin analog available, aimed at reducing side effects linked to preservatives. Aequus plans to use the funds for sales efforts, digital resources, and general working capital as it prepares for a critical product launch.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Aequus Pharmaceuticals Inc. (AQSZF) has received approval from Health Canada for Zimed® PF (Bimatoprost 0.03%), a preservative-free treatment for elevated intraocular pressure in patients with open-angled glaucoma and ocular hypertension. This innovative product, which utilizes a unique multi-dose bottle design, aims to improve patient adherence and reduce the risk of ocular surface disease typically associated with preservatives. The launch is set for 2023, with expectations for strong market uptake in Canada.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.27%
Tags
none
Aequus Pharmaceu

OTC:AQSZF

AQSZF Rankings

AQSZF Stock Data

517.27k
113.16M
14.68%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Canada
Vancouver